PCNA and Miyoshi myopathy: In a cohort of MM patients treated with high-dose melphalan and ASCT, polymorphisms of PARP, RAD51, PCNA, OGG1, XPC, BRCA1, ERCC1, BARD1, and TP53BP1 are associated with the outcome and overall survival of patients (Dumontet et al., 2010).